Alphatec Plunges 37%. A Bone-Graft Slump Hits the Spine Specialist’s Stock.
Alphatec slashes its full-year outlook as fewer surgeons have purchased its add-on bone-graft products used for spinal fusion.
Alphatec slashes its full-year outlook as fewer surgeons have purchased its add-on bone-graft products used for spinal fusion.